Literature DB >> 32857129

Genetic deficiency of Phactr1 promotes atherosclerosis development via facilitating M1 macrophage polarization and foam cell formation.

Te Li1, Lijuan Ding2, Yonggang Wang3, Ou Yang1, Shudong Wang3, Jian Kong1.   

Abstract

Genetic variants in phosphatase and actin regulator-1 (Phactr1) are reported to be associated with arteriosclerotic cardiovascular disease (ASCVD). However, the function of Phactr1 in atherosclerosis remains unclear. Patients with acute coronary syndrome (ACS) who underwent coronary angiography and optical coherence tomography (OCT) were enrolled and divided into non-ST segment elevation (NST-ACS) group and ST-ACS group. The expression of Phactr1 on monocytes was higher in NST-ACS and ST-ACS groups as compared with control group. Furthermore, NST-ACS patients who have more vulnerable features including thin-cap fibroatheroma (TCFA) and large lipid area showed higher levels of Phactr1 on monocytes than those with stable plaques. Through mouse models of atherosclerosis, Phactr1-/-Apoe-/- mice (double knockout mice, DKO) developed more severe atherosclerotic plaques, recruiting more macrophages into subendothelium and having elevated levels of proinflammatory cytokines in plaques. Similarly, Apoe knockout mice (Apoe-/-) receiving DKO bone marrow (BM) exhibited elevated plaque burden compared with Apoe-/- mice receiving Apoe-/- BM, indicating the protective effect of Phactr1 in hematopoietic cells. We found that depletion of Phactr1 in BM-derived macrophages (BMDMs) tended to differentiate into M1 phenotype, produced more proatherogenic cytokines and eventually converted into foam cells driven by oxidized low-density lipoprotein (ox-LDL). Mechanistically, Phactr1 activated CREB signaling via directly binding to CREB, up-regulating CREB phosphorylation and inducing KLF4 expression. Finally, overexpression of KLF4 partly rescued the excessive inflammation response and foam cell formation induced by deficiency of Phactr1. In conclusion, our study demonstrates that elevated Phactr1 in monocytes is a promising biomarker for vulnerable plaques, while increased Phactr1 attenuates atherosclerotic development via activation of CREB and M2 macrophage differentiation.
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  CREB signaling; Phactr1; acute coronary syndrome; foam cell; macrophage polarization

Mesh:

Substances:

Year:  2020        PMID: 32857129     DOI: 10.1042/CS20191241

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  5 in total

Review 1.  Inflammation Resolution: Implications for Atherosclerosis.

Authors:  Amanda C Doran
Journal:  Circ Res       Date:  2022-01-07       Impact factor: 17.367

2.  Deficiency of macrophage PHACTR1 impairs efferocytosis and promotes atherosclerotic plaque necrosis.

Authors:  Canan Kasikara; Maaike Schilperoort; Brennan Gerlach; Chenyi Xue; Xiaobo Wang; Ze Zheng; George Kuriakose; Bernhard Dorweiler; Hanrui Zhang; Gabrielle Fredman; Danish Saleheen; Muredach P Reilly; Ira Tabas
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

Review 3.  Pathogenesis of premature coronary artery disease: Focus on risk factors and genetic variants.

Authors:  Haiming Wang; Zifan Liu; Junjie Shao; Min Jiang; Xuechun Lu; Lejian Lin; Lin Wang; Qiang Xu; Haomin Zhang; Xin Li; Jingjing Zhou; Yundai Chen; Ran Zhang
Journal:  Genes Dis       Date:  2020-11-10

4.  MiR-92a/KLF4/p110δ regulates titanium particles-induced macrophages inflammation and osteolysis.

Authors:  Zhenkang Wen; Sipeng Lin; Changchuan Li; Zhuji Ouyang; Zhong Chen; Shixun Li; Yuxi Huang; Wenqiang Luo; Zhongcan Zheng; Peidong Guo; Manyuan Kuang; Yue Ding
Journal:  Cell Death Discov       Date:  2022-04-13

5.  PHACTR1, a coronary artery disease risk gene, mediates endothelial dysfunction.

Authors:  Xiaoxuan Ma; Meiming Su; Qingze He; Zhidan Zhang; Fanshun Zhang; Zhenghong Liu; Lu Sun; Jianping Weng; Suowen Xu
Journal:  Front Immunol       Date:  2022-08-25       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.